FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Medicare coverage debates amplify as FDA approves Rexulti for Alzheimer's agitation

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

REXULTI® (brexpiprazole) For Healthcare Professionals

FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

What is agitation that may happen with dementia due to Alzheimer's disease?

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease - Scioto Post

FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

Mark Oldham on X: I had no clue they were going for this indication! I need to read more about this. #Brexpiprazole is similar to aripiprazole, which is among the most prescribed

Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements

1st drug to treat dementia symptoms approved by FDA, agency says